MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
CRSP CRISPR Therapeutics
- 40.720
- +0.335+0.83%
Close Dec 20 16:00 ET
- 40.970
- +0.250+0.61%
Post 16:56 ET
3.48BMarket Cap-14.59P/E (TTM)
41.020High39.410Low3.34MVolume40.250Open40.385Pre Close134.71MTurnover3.98%Turnover RatioLossP/E (Static)85.35MShares91.10052wk High1.79P/B3.42BFloat Cap39.41052wk Low--Dividend TTM83.95MShs Float220.200Historical High--Div YieldTTM3.99%Amplitude11.630Historical Low40.283Avg Price1Lot Size
About CRISPR Therapeutics Company
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Company Profile
SymbolCRSP
Company NameCRISPR Therapeutics
Listing DateOct 19, 2016
Issue Price14.00
Founded2013
CEODr. Samarth Kulkarni, PhD
MarketNASDAQ
Employees407
Fiscal Year Ends12-31
AddressBaarerstrasse 14
CityZug
ProvinceZug
CountrySwitzerland
Zip Code6300
Phone41-41-561-32-77
Websitehttp://www.crisprtx.com
Company Executives
- Name
- Position
- Salary
- Dr. Samarth Kulkarni, PhD
- Chairman of the Board and Chief Executive Officer
- 12.32M
- Dr. Raju Prasad
- Chief Financial Officer and Principal Accounting Officer
- 5.72M
- Julianne Bruno
- Chief Operating Officer
- --
- Dr. Ali Behbahani, M.B.A.,M.D.
- Independent Director
- 545.06K
- Dr. Simeon J. George, M.B.A.,M.D.
- Independent Director
- 542.56K
- Dr. Katherine A. High, M.D.
- Independent Director
- 532.56K
- Dr. Christian Rommel, PhD
- Independent Director
- --
- John T. Greene
- Independent Director
- 555.06K
- Dr. Douglas A. Treco, PhD
- Lead Independent Director
- 552.56K
- Sandesh Mahatme, L.L.M.
- Independent Director
- --
- Dr. Maria Fardis, PhD
- Independent Director
- 532.84K
- Dr. H. Edward Fleming, M.D.
- Independent Director
- 536.24K
- James R. Kasinger
- General Counsel and Secretary
- 3.51M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
